Professor Cathy McKenzie appointed to UK’s first full professorial role in intensive care pharmacy

Professor David Jones receives RPS Hanbury Medal 2025

23 May 2025

This news story was published when the organisation was the Royal Pharmaceutical Society. The Royal Pharmaceutical Society (RPS) is proud to announce that Professor David Jones, Professor of Pharmaceutical and Biomaterial Engineering at Queen’s University Belfast, has been awarded the 2025 Hanbury Medal, in recognition for his outstanding scientific contributions to pharmaceutical sciences, education and innovation. Professor Jones is a leading expert in pharmaceutical engineering and biomaterials. Over his career, he has developed new ways to deliver medicines more effectively and safely — including drug-releasing implants, eye treatments for sight-threatening diseases and coatings for medical devices that help prevent infections. His work has resulted in over 70 commercialised products and devices that have improved the lives of patients around the world. He also co-founded two successful companies, Xiomateria and Re-Vana Therapeutics, which are bringing these products to market. Professor Jones is the only pharmacist to have been elected to three national academies — the Royal Academy of Engineering, the Academy of Medical Sciences and the Royal Irish Academy — a testament to his reputation across scientific disciplines. A passionate educator and mentor, he has redesigned pharmacy education programmes, supervised nearly 50 PhD students and authored widely used textbooks in pharmaceutics and pharmaceutical statistics. He has also served as Editor of the Journal of Pharmacy and Pharmacology since 2000. In response to receiving the Hanbury Medal, Professor Jones, said: “I am both stunned and delighted to have been awarded the 2025 Hanbury Medal. Previous winners of this award have been both giants in and leaders of pharmacy and pharmaceutical research, and they have inspired me at various stages in my career. For me to join this list of winners is truly humbling. It is a great honour to have been recognised for my contributions to pharmaceutical research and education, as well as to my profession, pharmacy, to which I owe so much. I would like to sincerely thank all my work colleagues and students (both past and present), as well as my family, who have been with me throughout this journey.” Paul Bennett, RPS Chief Executive Officer, said: “The Hanbury Medal remains an important award of the Royal Pharmaceutical Society in recognition of excellence in pharmaceutical science. Recipients of this prestigious award have been recognised for their pioneering work and reflects the importance that the Society places on pharmaceutical science and research, disciplines which underpin the profession of pharmacy and without which advancements in medicines and patient care would not occur. “Many congratulations to Professor Jones who joins an eminent list of past recipients going back to 1881 and whose passion for research and innovation and his pioneering work will be an inspiration to so many pharmaceutical scientists and pharmacists.” Amira Guirguis, Chair of the RPS Science and Research Committee, and Hanbury Medal panellist, said: "It was a privilege to judge the awarding of the 2025 Hanbury Medal, and Professor David Jones is a worthy winner. His pioneering research in pharmaceutical engineering and biomaterials has had a profound impact on both patient care and scientific advancement. From developing innovative drug delivery systems to mentoring the next generation of pharmaceutical scientists, Professor Jones exemplifies the values of excellence and innovation that the Hanbury Medal celebrates. “We also extend our gratitude to the Academy of Pharmaceutical Sciences for nominating Professor Jones, whose work continues to inspire innovation, elevate the importance of science and research, and drive excellence among pharmaceutical scientists and pharmacists." Click here for more information on the RPS Hanbury Medal Read more RCPharm news stories

Our response to Guild of Healthcare Pharmacists open letter

25 October 2024

This letter was published when the organisation was the Royal Pharmaceutical Society. Following the open letter sent to us by the Guild of Healthcare Pharmacists (GHP), we have responded to them and have set out our response below: Dear Rob, Thank you for your recent letter concerning our Constitution and Governance Review. The Royal Pharmaceutical Society (RPS) is currently engaged in a conversation with our members and the wider profession about our proposals for change and our ambition to become a Royal College. These proposals are being set out for pharmacists and pharmaceutical scientists (whether members or not) via a series of ‘roadshow’ engagement events across GB during October and November. A recurring focus of the conversations we are having at these events is our ambitions to integrate credentialing into the profession; some of the questions about credentialing are echoed in the Guild Council’s letter. We are happy to clarify the benefits we envisage will flow from the further embedding of credentialing and to address some of the other points raised by the Guild Council. The key purpose of RPS credentialing is to protect the public and the integrity of the pharmacy profession through assuring patient-focused pharmacists (i.e., roles that have a direct impact on individual patients and/or patient populations) working at advancing levels of post-registration practice. Defining and assuring post-registration professional standards is a fundamental activity for a royal college and thus fully aligned with our proposals for change. Credentialing provides considerable benefits for pharmacists and the system. For a pharmacist, credentialing can support a standard professional career structure which offers potential for advancement. Credentialing also engenders professional confidence and pride, increases professional cohesion and provides a mechanism by which the skills and capabilities of an individual are recognised. We have also heard from candidates about the benefits they have gained from successfully undertaking credentialing; including increased confidence, improved practice and greater integration within the wider multidisciplinary team. For the employer and wider system, credentialing provides an objective and validated assurance mechanism for employee capability within and across organisations which can inform fair and valid career progression and recruitment decisions, assure consistency across the system and improve workforce portability. It also provides a mechanism by which other health professionals and patients can recognise the level of practice of the pharmacy workforce. We have heard of pharmacists having to ‘re-prove’ their level of practice when they have moved employer, sector, or location, with some having to restart a training pathway from scratch to meet specific regional or national training requirements. This is not efficient or effective for the service, the employer or the pharmacist and is addressed by embedding credentialing in the profession. RPS, in collaboration with the pharmacy profession, has been developing our credentialing model over the last 4 to 5 years and we recognise there is much work ahead of us, in continued partnership with many others in the pharmacy ecosystem, to ensure the full value of credentialing can be realised to the benefit of pharmacists, patients and the public. The changes and opportunities that lie ahead for the pharmacy profession act as a call for action for this change. Medicines, and therefore pharmacy practice, are advancing and becoming more complex; this is mirrored by patients’ healthcare needs. In tandem, the role of the pharmacist in delivering healthcare services within the wider multidisciplinary team is evolving rapidly across community, primary, and secondary care settings, including the prescribing of medicines from point of registration from 2026. We recognise that collaboration is vital in order to enable the integration of credentialing, and we are committed to continued engagement with employers across GB during 2025 and beyond to highlight the value of credentialing for them and their employed pharmacists. We will continue working closely with the Chief Pharmaceutical Officers, Pharmacy Deans and other NHS leaders, and will collaborate with professional representative bodies and other stakeholders, to demonstrate the value credentialing brings to the profession, patients and the wider healthcare system. Introducing a formal progression model into the post-registration space will involve additional effort and cost but we believe that these will be proportionate to the benefit (to patients, pharmacists and the profession) they will bring. NHS education commissioners have already supported pharmacists to engage with credentialing by, for example, providing access to the RPS post-registration foundation e-Portfolio, supporting post-registration foundation candidates through credentialing via national training programmes and funding candidates through core advanced credentialing. We will continue to advocate for employer and system support for the further rollout of credentialing. Credentialing has already been integrated into NHS policy as a requirement to progress to consultant pharmacist roles, in all sectors, including the NHS managed sector, as articulated in the NHS Consultant Pharmacist Guidance. Integrating all levels of credentialing meaningfully into the profession will require collective action and support and achieving this will not be achieved by the RPS or any future royal college in isolation. To be fully woven into the profession, credentialing needs to be integrated into job descriptions, job plans and career progression (including remuneration). We continue to drive for this through our advocacy work. And of course, pharmacists need to be supported. We agree that ensuring pharmacists have the time, space and support to develop professional practice portfolios is essential to integrating credentialing meaningfully in the profession. We have advocated for this through our Protected Learning Time policy and we recognise the need for more effective job planning. RPS curricula describe the recommended level of commitment from employers required to support a pharmacist undergoing a credentialing pathway. We’d like to emphasise that RPS credentialing is not a micro credential in a specific area of clinical practice but the assurance of a level of practice. When credentialing at core advanced level, we are assuring clinical and non-clinical capabilities (for example leadership) which align to the multiprofessional definitions of advanced practice in other professions. Where there is a patient and system need for specific clinical definition and assurance, we will continue to collaboratively develop specialist curricula, as we have done recently in critical care with the UK Clinical Pharmacy Association (UKCPA) and mental health in collaboration with the College of Mental Health Pharmacy (CMHP). The requirements of the specialist curricula can be demonstrated at the same time as the core advanced credentialing process or separately, depending on the pharmacist’s career preferences. Moving away from the question of credentialing and considering the wider ambitions of our proposal for change, we must consider governance. Governance mechanisms exist to ensure appropriate decisions are made in line with the organisation’s ambitions. Our rigorous governance review aims to embed transparency in the way we work and ensure that the future Royal College remains led by the profession. Our intent to register as a charity further ensures that there are appropriate external frameworks and scrutiny in place so that we meet our intended objective of advancing the science and practice of pharmacy, with patient and public benefit at the forefront of our work. We look forward to constructive dialogue with the Guild Council over the coming months as we refine our proposals for change and prepare to set the final proposition before our membership for a vote in early 2025. Meanwhile we invite Guild members together with all pharmacists and pharmaceutical scientists to attend one of our roadshow events and/or to find out more about the proposals for change. Yours sincerely, Paul Bennett FRPharmS, Chief Executive, Royal Pharmaceutical Society